SUBSCRIBE
SUBSCRIBE
News   Drug Development

AVANIR Pharmaceuticals Announces Last Patient Enrolled In Neuropathic Pain Phase III Trial With Zenvia

November 15, 2006 | 
1 min read
SAN DIEGO--(BUSINESS WIRE)--AVANIR Pharmaceuticals (NASDAQ:AVNR) announced today that the Company has enrolled the targeted number of patients needed to assess the efficacy endpoint in its ongoing Zenvia Phase III painful diabetic neuropathy trial.
Clinical research Phase 3
MORE ON THIS TOPIC
Checklist collage banner with halftone hands. Hand holding marker and putting a check mark or cross in checkbox. Collage design with halftone elements. Concept of check list. Vector illustration.
Vaccines
Pfizer ‘Confident’ in Valneva-Partnered Lyme Vaccine Despite Missed Primary Endpoint
March 23, 2026
 · 
2 min read
 · 
Heather McKenzie
Hourglass lying on pink background - Concept of time and woman
Insights
Validated Mechanisms, Strong Data Beat Hype in Longevity Investing
March 23, 2026
 · 
3 min read
 · 
Jennifer C. Smith-Parker
Business people and concepts vector art exit
Spinal muscular atrophy
Roche Ends Run for Muscular Atrophy Drug, Leaving Door Open for Competitors
March 20, 2026
 · 
2 min read
 · 
Tristan Manalac
Man walking on a long wavy path with flag at the end, persistence, determination and ultimate business success - 3D Render
FDA
Sarepta Plans FDA Run for Duchenne Exon Skippers Despite Confirmatory Trial Failure
March 19, 2026
 · 
2 min read
 · 
Annalee Armstrong